bile acid binding proteins

closely related proteins (MW 33,000) from rat hepatic cytosol with bile acid binding activity; bile-salt binding polypeptides in brush-border membrane vesicles; separate record for pp120/HA4, a liver membrane glycoprotein with ectoATPase activity

Also Known As:

Networked: 123 relevant articles (8 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Geyer, Joachim: 6 articles (01/2022 - 10/2014)
2.	Camilleri, Michael: 6 articles (11/2019 - 10/2011)
3.	Nakajima, Atsushi: 5 articles (07/2022 - 01/2018)
4.	Glebe, Dieter: 5 articles (01/2022 - 10/2014)
5.	Taniguchi, Shinya: 5 articles (01/2019 - 01/2018)
6.	Goldmann, Nora: 4 articles (01/2022 - 01/2021)
7.	Kirstgen, Michael: 4 articles (01/2022 - 01/2021)
8.	Lehmann, Felix: 4 articles (01/2022 - 01/2021)
9.	Müller, Simon Franz: 4 articles (01/2022 - 01/2021)
10.	Lowjaga, Kira Alessandra Alicia Theresa: 3 articles (01/2022 - 01/2021)

Related Diseases

1.	Pruritus (Itching) 07/19/2016 - "BAT117213 study is the first randomised controlled crossover trial of ileal bile acid transporter inhibitor, a novel class of drug to treat pruritus in PBC. " 02/01/2021 - "GLIMMER Trial-A Randomized, Double-Blind, Placebo-Controlled Study of Linerixibat, an Inhibitor of the Ileal Bile Acid Transporter, in the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis." 07/19/2016 - "BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial." 07/01/2023 - "GLIMMER assessed dose-response, efficacy, and safety of linerixibat, an ileal bile acid transporter inhibitor in development for cholestatic pruritus associated with primary biliary cholangitis (PBC). " 03/08/2023 - "For cholestatic pruritus and liver disease development, bile acid transporter inhibition is a unique treatment strategy. "
2.	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 02/01/2021 - "GLIMMER Trial-A Randomized, Double-Blind, Placebo-Controlled Study of Linerixibat, an Inhibitor of the Ileal Bile Acid Transporter, in the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis." 07/19/2016 - "BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial." 07/01/2023 - "GLIMMER assessed dose-response, efficacy, and safety of linerixibat, an ileal bile acid transporter inhibitor in development for cholestatic pruritus associated with primary biliary cholangitis (PBC). " 12/01/2021 - "Linerixibat, an oral small-molecule ileal bile acid transporter inhibitor under development for cholestatic pruritus in primary biliary cholangitis, was designed for minimal absorption from the intestine (site of pharmacological action). " 01/01/2019 - "Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. "
3.	progressive familial intrahepatic 1 Cholestasis 03/08/2023 - "It is a tiny chemical that inhibits the ileal bile acid transporter and is used to treat a variety of cholestatic illnesses, including progressive familial intrahepatic cholestasis (PFIC). " 01/01/2019 - "Progressive familial intrahepatic cholestasis (PFIC) is a rare bile acid transporter defect and autosomal recessive disorder with type 2 being the most common type. " 01/01/2020 - "Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis." 08/01/2023 - "PEDFIC 2, an ongoing, open-label, 72-week study, evaluates odevixibat, an ileal bile acid transporter inhibitor, in patients with progressive familial intrahepatic cholestasis. " 01/01/2023 - "Odevixibat, an ileal bile acid transporter (IBAT) inhibitor, is effective for the treatment of pruritus in children diagnosed with progressive familial intrahepatic cholestasis (PFIC) type 1 and 2. There are no studies showing the efficacy of Odevixibat in children with different subtypes of PFIC. "
4.	Constipation 06/28/2015 - "Recently, the inhibition of the ileal bile acid transporter has become a promising target for constipation-associated diseases. " 06/28/2015 - "Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation." 07/01/2011 - "Ileal Bile Acid Transporter inhibition is a novel mechanism for treatment of patients with chronic idiopathic constipation and has additional benefits of improving metabolic parameters (EudraCT 2008-003255-72)." 06/28/2015 - "This article provides insight into the mechanism of action of ileal bile acid transporter inhibitors and discusses their potential clinical use for pharmacotherapy of constipation in chronic idiopathic constipation. " 01/01/2018 - "Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH."
5.	Hepatocellular Carcinoma (Hepatoma) 02/21/2012 - "A human hepatocellular carcinoma cell line stably transfected with a bile acid transporter (Huh-BAT cells), were used in this study. " 08/01/2006 - "Huh-BAT cells, a human hepatocellular carcinoma cell line stably transfected with a bile acid transporter, were used in this study. " 10/01/1997 - "Hepatocellular carcinomas express the Na(+)-dependent bile acid transporter NTCP. " 01/12/2021 - "Overexpression of the sodium taurocholate co-transporting polypeptide (NTCP) bile acid transporter in hepatoma cells improved infection efficiency. " 05/01/1996 - "Therapeutic strategies employing bile acid-derived cytostatic agents for the treatment of hepatocellular carcinomas may therefore depend upon the expression of the Na+-independent bile acid transporter OATP in hepatic malignancies."

Related Drugs and Biologics

1.	3- ((((3R,5R)- 3- butyl- 3- ethyl- 7- (methyloxy)- 1,1- dioxido- 5- phenyl- 2,3,4,5- tetrahydro- 1,4- benzothiazepin- 8- yl)methyl)amino)pentanedioic acid
2.	Bile Acids and Salts (Bile Acids)
3.	elobixibat
4.	Peptides (Polypeptides)
5.	Sodium
6.	odevixibat
7.	Carrier Proteins (Binding Protein)
8.	Soybean Proteins (Soy Protein)
9.	Taurocholic Acid (Sodium Taurocholate)
10.	Cholesterol

Related Therapies and Procedures

1.	Radiotherapy
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)